Skip to main content

Advertisement

Table 2 Comparison of adverse events in the sorafenib and sunitinib groups

From: Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

Adverse event Sorafenib group [cases (%)] Sunitinib group [cases (%)] P value*
All grade Grade 1–2 Grade 3–4 All grade Grade 1–2 Grade 3–4
Hypertension 23 (20.9) 22 (20.0) 1 (0.9) 23 (36.0) 20 (32.4) 3 (3.6) 0.050
Hand–foot syndrome 74 (67.3) 66 (60.0) 8 (7.3) 44 (59.5) 44 (59.5) 0 (0.0) 0.279
Diarrhea 69 (62.7) 67 (60.9) 2 (1.8) 26 (35.2) 23 (31.1) 3 (4.1) <0.001
Nausea 41 (37.3) 41 (37.3) 0 (0.0) 29 (39.2) 29 (39.2) 0 (0.0) 0.793
Fatigue 42 (38.2) 42 (38.2) 0 (0.0) 33 (44.6) 33 (44.6) 0 (0.0) 0.385
Alopecia 9 (8.2) 9 (8.2) 0 (0.0) 7 (9.5) 7 (9.5) 0 (0.0) 0.763
Leukocytopenia 12 (10.9) 12 (10.9) 0 (0.0) 27 (36.5) 24 (32.4) 3 (4.1) <0.001
Anemia 20 (18.2) 18 (16.4) 2 (1.8) 9 (12.2) 9 (12.2) 0 (0.0) 0.272
Thrombocytopenia 12 (10.9) 12 (10.9) 0 (0.0) 30 (40.5) 28 (37.8) 2 (2.7) <0.001
Hypothyroidism 4 (3.6) 4 (3.6) 0 (0.0) 13 (17.6) 13 (17.6) 0 (0.0) 0.001
Elevation of ALT 11 (10.0) 10 (9.1) 1 (0.9) 10 (13.5) 10 (13.5) 0 (0.0) 0.462
  1. ALT alanine aminotransferase
  2. * Grade 1–2 and grade 3–4 toxicities were combined for the comparison